Who Can't Have Weight Loss Injections? (October 2026)

01 · The core answer

The short answer: who can't have weight loss injections

People who fall outside the licence, or whose history makes the medicine unsafe for them, can't have weight loss injections. Mounjaro is the brand name for tirzepatide, a once-weekly injectable prescription medicine made by Eli Lilly. In the UK it is licensed for weight management in adults and for type 2 diabetes.¹ That already excludes anyone who is not an adult, and anyone who wants it for a purpose outside the licence.

Mounjaro is not suitable for everyone. You should not take it if you are allergic to tirzepatide or any of its ingredients, and it should not be used during pregnancy or while trying to conceive.¹¹³ Mounjaro must not be used during pregnancy, and it should be stopped at least one month before trying to conceive. If you become pregnant during treatment, stop the medicine and tell your prescriber promptly. Your prescriber will take extra care, or may recommend against treatment, if you have a history of pancreatitis, severe gut or digestive disease, diabetic retinopathy, or gallbladder problems. Always share your full medical history and medicine list during consultation.

It is also a prescription-only medicine. It is supplied only after an online consultation reviewed by a GPhC-registered prescriber, and it is used alongside a reduced-calorie diet and increased physical activity. Individual results vary.¹

02 · What to do next

The decisions you are actually facing

Most readers are asking one of two things: am I ruled out, or why was I declined? For the first, the quickest route is to read the leaflet and then complete a consultation. Our guide to whether you can have weight loss injections covers the positive side of eligibility. The consultation is free, carries no obligation, and a prescriber, not a scoring script, makes the call.

For the second question, a decline is rarely about one rule. It is usually a combination of your history, your current medicines and the licensed criteria.

If you want to see where you stand, the Mounjaro pen page starts the free consultation. Your first 2.5mg pen costs £129.99 with code FIRST40 (standard price £169.99); payment is taken when you place the order, and if the prescriber decides the treatment is not suitable, the order is refunded automatically in full.

If you are researching more widely, our weight loss clinic hub sets out the other routes we cover.

03 · What the licence covers

What the Mounjaro licence covers, and what it doesn't

The licence defines the first group of people who can't have the injection: anyone outside it. Mounjaro is the brand name for tirzepatide, a once-weekly injectable prescription medicine. In the UK it is licensed for weight management in adults and for type 2 diabetes.¹ It comes as a pre-filled multi-dose pen, the KwikPen, in six strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg.¹

A licence is not a loose recommendation. It is the set of uses for which the manufacturer has shown safety and benefit to the regulator. When someone asks for a weight loss injection for cosmetic reasons, for a younger family member, or in a way the pen was never designed for, a registered pharmacy has no basis to supply it.

That is why a prescriber reviews every request. The BNF entry for tirzepatide sets out indications, dosing and safety information in a form clinicians use daily.¹¹ We follow the same framework. If your situation sits outside it, a polite no is the safe answer.

It is also worth separating can't from shouldn't yet. Some people are declined today and become suitable later, for example when a circumstance changes or a condition is better controlled. A decline is a snapshot of the current picture, not a permanent label.

Finally, the licence assumes the medicine is used alongside a reduced-calorie diet and increased physical activity. Someone hoping the injection will replace those entirely is working from a mistaken premise, and the prescriber is likely to say so. If you want the broader picture of who prescribes and supplies these medicines, our guide on who can prescribe weight loss injections is a good companion read.

04 · NHS criteria

Who can't have it on the NHS yet

On the NHS, many adults who would be suitable clinically can't yet have the injection simply because access is being phased in. Mounjaro is available on the NHS, but access is being phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition.⁴ The primary-care rollout began in June 2025 with the highest-need groups first, initially BMI 40+ with four or more qualifying conditions.⁶

So the NHS answer to who can't have weight loss injections has two layers. The first is the national recommendation, which sets a BMI floor and requires a weight-related condition. The second is the rollout order, which means even people who meet the recommendation may wait their turn. Full rollout is expected to take years.

That is frustrating, and it explains why many people who meet the licensed criteria choose regulated private treatment rather than waiting. It does not mean private treatment is a shortcut around safety. The same clinical questions apply, and a prescriber can still decline.

If you think you may qualify on the NHS, speak to your GP and read the NHS guidance on tirzepatide.⁵ Our own explainer on having weight loss injections on the NHS goes through the practical steps. NHS access to Wegovy runs through specialist weight-management services; ask your GP.

One practical point: being told the NHS can't offer it yet is not the same as being told you are unsuitable. Ask your GP which of those two answers applies to you, because the next step differs. The first sends you to wait or look at other options. The second tells you something about your health that should shape any decision to buy privately.

05 · The prescriber review

How a prescriber decides who can't have it

A GPhC-registered prescriber decides, from your answers, whether the injection is appropriate and safe for you. Our process starts with a free online consultation: a short health questionnaire, no charge and no obligation. The prescriber then reviews it. That person is a clinician, not a scoring script.

The review weighs your answers against the SmPC and leaflet, your current medicines and your goals. If something is unclear, a clinician can ask follow-up questions rather than reject you outright. Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full.

The consultation only protects you if the answers are true and complete. Leaving out a condition or a medicine to get approved defeats the purpose, because the review is the safety check. Tell the prescriber everything, including supplements and anything you take occasionally.

Repeat orders re-check suitability too, and nothing is auto-shipped. Your circumstances can change between orders, and the prescribing team provides ongoing monthly reviews, dose-titration and follow-up assessments, plus side-effect support. A person who was suitable at the start can become unsuitable later, and the system is built to catch that.

For the practical side of what happens once you are approved, our page on who gives weight loss injections compares the main routes. Our online registration guide shows what signing up involves. The consultation is free, and the price shown is the price paid.

06 · Other medicines

Other medicines that change the answer

Some people can have the injection only with changes to their other medicines, so your full medicine list matters. Two interactions are worth knowing about, and both are about adjustment, not automatic exclusion.

The first is oral contraception. The SmPC advises switching to a non-oral method, or adding a barrier method (such as condoms), for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase.¹ The medicine can reduce absorption of oral contraceptives, because stomach emptying slows.⁷ The MHRA has published guidance on contraception with GLP-1 and GIP medicines. If you use the pill, tell the prescriber, and switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose increase.

The second is insulin and sulfonylureas. Doses of these may need adjusting because of the risk of low blood sugar. That is not the same as saying they must never be combined with Mounjaro. It means a clinician should be involved, ideally the one managing your diabetes, so changes are planned rather than improvised.

How the medicine works explains why interactions arise. Tirzepatide activates two natural gut-hormone receptors at once, GIP and GLP-1. Together these help regulate appetite, slow how quickly the stomach empties, and improve the way the body responds to insulin.¹ Anything absorbed from the stomach, or anything that lowers blood sugar, can be affected by that action.

The same logic applies to anything not mentioned here. The safe approach is simple: list everything you take on the consultation form, and read the leaflet's section on other medicines. If a prescriber asks you to pause or change something, follow their guidance and never alter another prescribed treatment on your own. Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing.

07 · Reasons for a decline

Why you might be declined, and what it does not mean

Being declined usually reflects one of a few categories, and none is a judgement on your character or effort.

The commonest category is the licence itself: you may be outside the age range, or the treatment may not match what the medicine is licensed for. The next is a health circumstance that the official documents flag as a reason not to use the medicine, or to use it only under closer supervision. Another is a medicine interaction, where the prescriber judges the combination too risky to manage remotely.

A further category is incomplete information. If your answers leave real doubt, a careful prescriber would rather pause than guess. In that case you may be asked for more detail, or advised to see your GP first so that a clinician who knows your history can weigh in.

What a decline does not mean: that you failed, that your weight concerns are not real, or that nothing else can help. Sensible alternatives include speaking to your GP, asking about NHS weight-management services, and revisiting the question if your circumstances change.

If you want to know why you personally can't get an injection, the answer is on your consultation record. Ask the prescribing team, or contact our support team Monday to Friday, 9am to 5pm, at support@everydaymeds.co.uk or on 0333 207 0413. Our wider explainer on who cannot have weight loss injections adds more context.

08 · Stopping and review

When someone who could have it should stop

A person can be suitable at the start and still be advised to stop, so who can have the injection is not fixed. Your prescriber reviews how you respond. If you have lost less than 5% of your starting weight after 6 months on the highest dose you can tolerate, your prescriber will discuss whether continuing or stopping is right for you.¹

Pace matters here. Weight loss on Mounjaro is gradual by design. The first weeks on 2.5mg are an adjustment phase and losses are usually modest. Most measurable progress builds from 5mg onward, month by month.¹ Trials measured results at 72 weeks, so think in months, not days.

For context on what the medicine can do, in SURMOUNT-1 people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.² These are trial averages and individual results vary. A trial average does not predict your own result.

If you stop, tirzepatide has a half-life of about five days, so after a final dose it takes roughly four to five weeks to clear the system. There is no way to speed this up, and nothing needs doing while it clears.¹

Stopping is a conversation, not a failure.

09 · Safe supply and alternatives

If you can't have it: safe supply and alternatives

If you are told you can't have the injection, the worst response is to buy it elsewhere without a prescription. Be wary of anyone offering to supply without a consultation or prescription. Counterfeit weight-loss pens have been the subject of MHRA alerts, and the MHRA also runs the Yellow Card scheme for reporting side effects and suspected fake medicines.⁷¹⁹

A genuine supplier is easy to check. EverydayMeds is GPhC-registered, number 9012878, and you can look us up on the GPhC register. Our Mounjaro comes direct from Eli Lilly's UK distribution through official LillyDirect supply, and the pens are genuine KwikPens.

If you are not suitable, the useful next steps are non-medicinal and medical. Speak to your GP about weight-management support. Ask about NHS services. Ask whether a different licensed treatment might suit you better, since that is a decision for a clinician who knows your history.

Low-cost supplements sold as natural alternatives are available without assessment, but they carry no clinical oversight, and dramatic weight-loss claims made for them should be treated with scepticism. Our page on colostrum weight loss injections looks at one such claim.

If you are suitable and ready, the Mounjaro pen is in stock across all six doses. Orders placed by 3pm are dispatched the same day, with free next-day tracked delivery in temperature-controlled packaging. Saturday delivery is £14.99. Prices were checked 11 October 2026. New customers save £40 on their first order with code FIRST40, and every later order is £25 off the standard price.